$72.03
Insights on Boston Scientific Corp.
Revenue is up for the last 3 quarters, 3.52B → 3.85B (in $), with an average increase of 4.4% per quarter
Netprofit is down for the last 2 quarters, 505.0M → 494.0M (in $), with an average decrease of 2.2% per quarter
1.42%
Downside
Day's Volatility :2.05%
Upside
0.63%
32.88%
Downside
52 Weeks Volatility :35.0%
Upside
3.17%
Period | Boston Scientific Corp. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 11.74% | -1.1% | 2.1% |
6 Months | 37.12% | 10.3% | 16.2% |
1 Year | 36.71% | 5.3% | 23.8% |
3 Years | 65.09% | 14.5% | 20.8% |
Market Capitalization | 107.2B |
Book Value | $13.16 |
Earnings Per Share (EPS) | 1.07 |
PE Ratio | 68.14 |
PEG Ratio | 1.8 |
Wall Street Target Price | 74.2 |
Profit Margin | 11.18% |
Operating Margin TTM | 16.56% |
Return On Assets TTM | 4.47% |
Return On Equity TTM | 8.58% |
Revenue TTM | 14.2B |
Revenue Per Share TTM | 9.8 |
Quarterly Revenue Growth YOY | 14.899999999999999% |
Gross Profit TTM | 8.7B |
EBITDA | 3.6B |
Diluted Eps TTM | 1.07 |
Quarterly Earnings Growth YOY | 2.86 |
EPS Estimate Current Year | 2.25 |
EPS Estimate Next Year | 2.55 |
EPS Estimate Current Quarter | 0.51 |
EPS Estimate Next Quarter | 0.52 |
What analysts predicted
Upside of 3.01%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 9.8B | ↑ 8.57% |
Net Income | 1.7B | ↑ 1506.73% |
Net Profit Margin | 17.01% | ↑ 15.86% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 10.7B | ↑ 9.28% |
Net Income | 4.7B | ↑ 181.27% |
Net Profit Margin | 43.78% | ↑ 26.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 9.9B | ↓ 7.66% |
Net Income | -140.0M | ↓ 102.98% |
Net Profit Margin | -1.41% | ↓ 45.19% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 11.9B | ↑ 19.92% |
Net Income | 1.0B | ↓ 843.57% |
Net Profit Margin | 8.76% | ↑ 10.17% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 12.7B | ↑ 6.68% |
Net Income | 698.0M | ↓ 32.95% |
Net Profit Margin | 5.5% | ↓ 3.26% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 14.2B | ↑ 12.29% |
Net Income | 1.6B | ↑ 128.22% |
Net Profit Margin | 11.19% | ↑ 5.69% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.2B | ↑ 2.27% |
Net Income | 140.0M | ↓ 19.54% |
Net Profit Margin | 4.32% | ↓ 1.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.4B | ↑ 4.53% |
Net Income | 314.0M | ↑ 124.29% |
Net Profit Margin | 9.27% | ↑ 4.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6B | ↑ 6.2% |
Net Income | 270.0M | ↓ 14.01% |
Net Profit Margin | 7.5% | ↓ 1.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↓ 2.0% |
Net Income | 504.0M | ↑ 86.67% |
Net Profit Margin | 14.29% | ↑ 6.79% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 5.61% |
Net Income | 505.0M | ↑ 0.2% |
Net Profit Margin | 13.56% | ↓ 0.73% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.9B | ↑ 3.52% |
Net Income | 494.0M | ↓ 2.18% |
Net Profit Margin | 12.81% | ↓ 0.75% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 21.0B | ↑ 10.28% |
Total Liabilities | 12.3B | ↑ 2.02% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.6B | ↑ 45.56% |
Total Liabilities | 16.7B | ↑ 35.97% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 30.8B | ↑ 0.7% |
Total Liabilities | 15.5B | ↓ 7.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 32.2B | ↑ 4.72% |
Total Liabilities | 15.6B | ↑ 1.01% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 32.5B | ↑ 0.74% |
Total Liabilities | 14.9B | ↓ 4.56% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 35.1B | ↑ 8.21% |
Total Liabilities | 15.6B | ↑ 4.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 32.5B | ↑ 1.63% |
Total Liabilities | 14.9B | ↑ 4.12% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.9B | ↑ 1.3% |
Total Liabilities | 14.8B | ↓ 0.76% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.6B | ↑ 2.16% |
Total Liabilities | 15.1B | ↑ 2.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.0B | ↑ 1.32% |
Total Liabilities | 14.9B | ↓ 1.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 35.1B | ↑ 3.21% |
Total Liabilities | 15.6B | ↑ 4.64% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 310.0M | ↓ 78.26% |
Investing Cash Flow | -1.9B | ↑ 90.2% |
Financing Cash Flow | 1.4B | ↑ 1201.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 492.26% |
Investing Cash Flow | -5.0B | ↑ 162.42% |
Financing Cash Flow | 3.0B | ↑ 107.61% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 17.86% |
Investing Cash Flow | -411.0M | ↓ 91.85% |
Financing Cash Flow | 293.0M | ↓ 90.14% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↑ 24.01% |
Investing Cash Flow | -1.6B | ↑ 288.56% |
Financing Cash Flow | -95.0M | ↓ 132.42% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 18.4% |
Investing Cash Flow | -2.0B | ↑ 25.92% |
Financing Cash Flow | -548.0M | ↑ 476.84% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 470.0M | ↑ 53.09% |
Investing Cash Flow | -225.0M | ↑ 675.86% |
Financing Cash Flow | -199.0M | ↓ 42.15% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 807.0M | ↑ 71.7% |
Investing Cash Flow | -2.0B | ↑ 793.78% |
Financing Cash Flow | 1000.0K | ↓ 100.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 190.0M | ↓ 76.46% |
Investing Cash Flow | -484.0M | ↓ 75.93% |
Financing Cash Flow | -69.0M | ↓ 7000.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 658.0M | ↑ 246.32% |
Investing Cash Flow | -840.0M | ↑ 73.55% |
Financing Cash Flow | 43.0M | ↓ 162.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 698.0M | ↑ 6.08% |
Investing Cash Flow | -1.5B | ↑ 81.07% |
Financing Cash Flow | 16.0M | ↓ 62.79% |
Sell
Neutral
Buy
Boston Scientific Corp. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Boston Scientific Corp. | 5.72% | 37.12% | 36.71% | 65.09% | 93.63% |
Stryker Corporation | -6.94% | 18.25% | 13.75% | 24.15% | 71.27% |
Edwards Lifesciences Corp. | -8.56% | 26.82% | -3.45% | -10.11% | 40.59% |
Abbott Laboratories | -4.82% | 10.52% | -5.23% | -11.39% | 34.6% |
Medtronic Plc | -4.8% | 11.52% | -10.77% | -38.32% | -9.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Boston Scientific Corp. | 68.14 | 68.14 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Stryker Corporation | 40.83 | 40.83 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Edwards Lifesciences Corp. | 37.58 | 37.58 | 5.19 | 2.75 | 0.21 | 0.12 | NA | 11.83 |
Abbott Laboratories | 33.3 | 33.3 | 5.99 | 4.6 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.52 | 25.52 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Boston Scientific Corp. | Buy | $107.2B | 93.63% | 68.14 | 11.18% |
Stryker Corporation | Buy | $128.2B | 71.27% | 40.83 | 15.44% |
Edwards Lifesciences Corp. | Buy | $52.0B | 40.59% | 37.58 | 23.01% |
Abbott Laboratories | Buy | $185.5B | 34.6% | 33.3 | 13.96% |
Medtronic Plc | Buy | $106.7B | -9.67% | 25.52 | 13.0% |
FMR Inc
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Massachusetts Financial Services Company
PRIMECAP Management Company
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
Organization | Boston Scientific Corp. |
Employees | 48000 |
CEO | Mr. Michael F. Mahoney |
Industry | Health Technology |